Sphera Funds Management Ltd. Vertex Pharmaceuticals Inc Transaction History

Sphera Funds Management Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $976,683 - $1.15 Million	-4,411 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $780,791 - $985,637	4,411 New	4,411 $969,000
Q2 2021 Aug 17, 2021	SELL	$187.49 - $221.1 $1.04 Million - $1.22 Million	-5,530 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$207.02 - $241.31 $1.14 Million - $1.33 Million	5,530 New	5,530 $1.19 Million
Q2 2020 Aug 13, 2020	SELL	$225.48 - $295.8 $1.58 Million - $2.07 Million	-7,000 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$199.77 - $247.81 $1.4 Million - $1.73 Million	7,000 New	7,000 $1.67 Million
Q3 2018 Nov 14, 2018	SELL	$167.73 - $192.74 $3.35 Million - $3.85 Million	-20,000 Closed	0 $0
Q2 2018 Aug 13, 2018	BUY	$145.72 - $169.96 $2.91 Million - $3.4 Million	20,000 New	20,000 $3.4 Million
Q1 2018 May 10, 2018	SELL	$151.6 - $177.13 $13 Million - $15.2 Million	-85,823 Closed	0 $0
Q4 2017 Feb 12, 2018	BUY	$137.28 - $155.55 $8.92 Million - $10.1 Million	65,000 Added 312.15%	85,823 $12.9 Million
Q3 2017 Nov 09, 2017	BUY	$148.13 - $162.24 $3.08 Million - $3.38 Million	20,823	20,823 $3.17 Million

1,716

225M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Sphera Funds Management Ltd. with notifications on news.